glp 1 agonists anesthesia GLP-1 medications safe to continue before surgery in patients with diabetes and obesity Perioperative Management of GLP-1 RAs

Another 2025 survey published in JAMA Health Forum noted that, should Medicare pay for the drugs, it could avoid spending a hypothetical $18.2 billion on obesity-related health expenditures over 10 years while dishing out $65.9 billion annually on the GLP-1s by year 10, thereby negating any savings

One RCT examined the efficacy of liraglutide (up to 1.8 mg daily) in patients with psoriasis and T2DM over 12 weeks

10.1186/s12933-021-01366-8 64

& Singh, P

The CDMO capacity that exists for complex peptide manufacturing in 2026 is more constrained than any other segment of the pharmaceutical contract manufacturing market

In the US, GLP-1 spending rose from $13 to $72 billion in just five years, making approval tough for patients without diabeteseven as data for arthritis risk and cardiovascular benefits grow